Data driven prioritization and review of targets for molecular based theranostic approaches in pancreatic cancer

Data driven prioritization and review of targets for molecular based theranostic approaches in pancreatic cancer. J Nucl Med. 2017 Oct 19. pii: jnumed.117.198440. doi: 10.2967/jnumed.117.198440. [Epub ahead of print] # contributed equally Koller M, Hartmans E, de Groot DJA, Zhao XJ, van Dam GM, Nagengast WB#, Fehrmann RSN# Molecular targeted therapeutical and imaging strategies directed…

Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape

Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape. ESMO Open; DOI: 10.1136/esmoopen-2017-000272 Sjoukje F Oosting, Rudolf S Fehrmann, Elisabeth G E de Vries In the Oxford dictionary, ‘Independent’ is defined as ‘Free from outside control; not subject to another’s authority’. Independence can be critical to identify important issues for patients. The…

The antibody-drug conjugate target landscape across a broad range of tumour types

The antibody-drug conjugate target landscape across a broad range of tumour types Annals of Oncology, mdx541, https://doi.org/10.1093/annonc/mdx541 K.L. Moek D.J.A. de Groot E.G.E. de Vries R.S.N. Fehrmann Background Antibody-drug conjugates (ADCs), consisting of an antibody designed against a specific target at the cell membrane linked with a cytotoxic agent, are an emerging class of therapeutics.…

Theranostics Using Antibodies and Antibody-Related Therapeutics

Theranostics Using Antibodies and Antibody-Related Therapeutics. J Nucl Med. 2017 Sep;58(Suppl 2):83S-90S. doi: 10.2967/jnumed.116.186940. Kirsten L. Moek, Danique Giesen, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Rudolf S.N. Fehrmann, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers and Elisabeth G.E. de Vries In theranostics, radiolabeled compounds are used to determine a treatment strategy…

Carlos Urzua joins the group

Carlos is a medical doctor from Mexico with good bioinformatical skills. So I’m very happy that Carlos with his rare combination of skills is joining our group. Carlos previously was a topmaster student in the Medical Pharmaceutical Drug Innovation (MPDI) topmaster at the University of Groningen / University Medical Center Groningen and worked in my…

POINTING project will be funded by the KWF!

I’m very happy to announce that we have received good news from the Dutch Cancer Society. The project: ‘POINTING: Towards patient-tailored cancer immunotherapy supported by a multifaceted predictive signature composed of integrative omics and molecular imaging’ will receive funding from the ‘PROGRAMME RESEARCH & IMPLEMENTATION CALL 2016-I’. As one of the four principal investigators on…

New master student Carlos G. Urzua Traslavina

As of first of November, Carlos G. Urzua Traslavina joined the group for a 6 month project. Carlos is a topmaster student in the Medical Pharmaceutical Drug Innovation (MPDI) topmaster. He will be working on the subject: Classifying primary unknowns with gene expression profiles and neural networks. Very happy with that a MD is excited…

Young Academy Groningen launched

Very happy with the fact that yesterday the Young Academy Groningen was launched! As outlined on the University of Groningen site: The Young Academy of Groningen are a group of enthusiastic top young researchers who, in addition to their research programs, are driven by an interest in the broader aspects of science, including outreach, diversity,…